Open Access

Journal of Experimental and Clinical Cancer Research, volume 38, issue 1, publication number 156

Clinical development of targeted and immune based anti-cancer therapies

Seebacher N A ¹

Stacy A E ²

Porter G M ³

Merlot Angelica M ^{3, 4, 5}

Hide authors affiliations Show authors affiliations: 5 affiliations

Faculty of Medicine, The University of Sydney, Camperdown, Australia |

Faculty of Medicine, The University of Notre Dame, Darlinghurst, Australia |

Children’s Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Kensington, Australia |

⁴

School of Women’s and Children’s Health, Faculty of Medicine, University of New South Wales, Kensington, Australia |

⁵

UNSW Centre for Childhood Cancer Research, Faculty of Medicine, University of New South Wales, Kensington, Australia |

Publication type: Journal Article

Publication date: 2019-04-11

Springer Nature

Journal: Journal of Experimental and Clinical Cancer Research

Quartile SCImago

Quartile WOS

Impact factor: 11.3

ISSN: 03929078, 17569966

DOI: 10.1186/s13046-019-1094-2

Copy DOI

PubMed ID: 30975211

Cancer Research

Oncology

Abstract

Cancer is currently the second leading cause of death globally and is expected to be responsible for approximately 9.6 million deaths in 2018. With an unprecedented understanding of the molecular pathways that drive the development and progression of human cancers, novel targeted therapies have become an exciting new development for anti-cancer medicine. These targeted therapies, also known as biologic therapies, have become a major modality of medical treatment, by acting to block the growth of cancer cells by specifically targeting molecules required for cell growth and tumorigenesis. Due to their specificity, these new therapies are expected to have better efficacy and limited adverse side effects when compared with other treatment options, including hormonal and cytotoxic therapies. In this review, we explore the clinical development, successes and challenges facing targeted anti-cancer therapies, including both small molecule inhibitors and antibody targeted therapies. Herein, we introduce targeted therapies to epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), human epidermal growth factor receptor 2 (HER2), anaplastic lymphoma kinase (ALK), BRAF, and the inhibitors of the T-cell mediated immune response, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein-1 (PD-1)/ PD-1 ligand (PD-1 L).

By date By citations

Citations by journals

	1 2 3 4 5 6
Molecules	Molecules, 6, 3.7% Molecules 6 publications, 3.7%
Cancers	Cancers, 5, 3.09% Cancers 5 publications, 3.09%
Frontiers in Pharmacology	Frontiers in Pharmacology, 4, 2.47% Frontiers in Pharmacology 4 publications, 2.47%
Frontiers in Oncology	Frontiers in Oncology, 4, 2.47% Frontiers in Oncology 4 publications, 2.47%
Biomedicines	Biomedicines, 4, 2.47% Biomedicines 4 publications, 2.47%
International Journal of Molecular Sciences	International Journal of Molecular Sciences, 3, 1.85% International Journal of Molecular Sciences 3 publications, 1.85%
Cells	Cells, 3, 1.85% Cells 3 publications, 1.85%
PLoS Computational Biology	PLoS Computational Biology, 2, 1.23% PLoS Computational Biology 2 publications, 1.23%
Future Medicinal Chemistry	Future Medicinal Chemistry, 2, 1.23% Future Medicinal Chemistry 2 publications, 1.23%
Pharmaceutics	Pharmaceutics, 2, 1.23% Pharmaceutics 2 publications, 1.23%
Bioorganic and Medicinal Chemistry Letters	Bioorganic and Medicinal Chemistry Letters, 2, 1.23% Bioorganic and Medicinal Chemistry Letters 2 publications, 1.23%
ChemistrySelect	ChemistrySelect, 2, 1.23% ChemistrySelect 2 publications, 1.23%
RSC Advances	RSC Advances, 2, 1.23% RSC Advances 2 publications, 1.23%
Nutrition and Health	Nutrition and Health, 1, 0.62% Nutrition and Health 1 publication, 0.62%
Current Pharmaceutical Design	Current Pharmaceutical Design, 1, 0.62% Current Pharmaceutical Design 1 publication, 0.62%
Future Oncology	Future Oncology, 1, 0.62% Future Oncology 1 publication, 0.62%
Oncotarget	Oncotarget, 1, 0.62% Oncotarget 1 publication, 0.62%
DNA and Cell Biology	DNA and Cell Biology, 1, 0.62% DNA and Cell Biology 1 publication, 0.62%
International Journal of Molecular Medicine	International Journal of Molecular Medicine, 1, 0.62% International Journal of Molecular Medicine 1 publication, 0.62%
Journal of Neuro-Ophthalmology	Journal of Neuro-Ophthalmology, 1, 0.62% Journal of Neuro-Ophthalmology 1 publication, 0.62%
Medicine (United States)	Medicine (United States), 1, 0.62% Medicine (United States) 1 publication, 0.62%
World Journal of Clinical Cases	World Journal of Clinical Cases, 1, 0.62% World Journal of Clinical Cases 1 publication, 0.62%
Journal of Telemedicine and Telecare	Journal of Telemedicine and Telecare, 1, 0.62% Journal of Telemedicine and Telecare 1 publication, 0.62%
Human and Experimental Toxicology	Human and Experimental Toxicology, 1, 0.62% Human and Experimental Toxicology 1 publication, 0.62%
Vaccines	Vaccines, 1, 0.62% Vaccines 1 publication, 0.62%
Frontiers in Endocrinology	Frontiers in Endocrinology, 1, 0.62% Frontiers in Endocrinology 1 publication, 0.62%
Frontiers in Cell and Developmental Biology	Frontiers in Cell and Developmental Biology, 1, 0.62% Frontiers in Cell and Developmental Biology 1 publication, 0.62%
Journal of Experimental and Clinical Cancer Research	Journal of Experimental and Clinical Cancer Research, 1, 0.62% Journal of Experimental and Clinical Cancer Research 1 publication, 0.62%
Nature	Nature, 1, 0.62% Nature 1 publication, 0.62%
	1 2 3 4 5 6

Citations by publishers

	5 10 15 20 25 30
Elsevier	Elsevier, 27, 16.67% Elsevier 27 publications, 16.67%
Springer Nature	Springer Nature, 25, 15.43% Springer Nature 25 publications, 15.43%
Multidisciplinary Digital Publishing Institute (MDPI)	Multidisciplinary Digital Publishing Institute (MDPI), 24, 14.81% Multidisciplinary Digital Publishing Institute (MDPI) 24 publications, 14.81%
Wiley	Wiley, 13, 8.02% Wiley 13 publications, 8.02%
Frontiers Media S.A.	Frontiers Media S.A., 10, 6.17% Frontiers Media S.A. 10 publications, 6.17%
Future Medicine	Future Medicine, 4, 2.47% Future Medicine 4 publications, 2.47%
SAGE	SAGE, 3, 1.85% SAGE 3 publications, 1.85%
Bentham Science	Bentham Science, 3, 1.85% Bentham Science 3 publications, 1.85%
Public Library of Science (PLoS)	Public Library of Science (PLoS), 3, 1.85% Public Library of Science (PLoS) 3 publications, 1.85%
Wolters Kluwer Health	Wolters Kluwer Health, 3, 1.85% Wolters Kluwer Health 3 publications, 1.85%
American Chemical Society (ACS)	American Chemical Society (ACS), 3, 1.85% American Chemical Society (ACS) 3 publications, 1.85%
Spandidos Publications	Spandidos Publications, 2, 1.23% Spandidos Publications 2 publications, 1.23%
Royal Society of Chemistry (RSC)	Royal Society of Chemistry (RSC), 2, 1.23% Royal Society of Chemistry (RSC) 2 publications, 1.23%
Open Exploration Publishing	Open Exploration Publishing, 2, 1.23% Open Exploration Publishing 2 publications, 1.23%
Hindawi Limited	Hindawi Limited, 2, 1.23% Hindawi Limited 2 publications, 1.23%
Impact Journals	Impact Journals, 1, 0.62% Impact Journals 1 publication, 0.62%
Mary Ann Liebert	Mary Ann Liebert, 1, 0.62% Mary Ann Liebert 1 publication, 0.62%
Baishideng Publishing Group	Baishideng Publishing Group, 1, 0.62% Baishideng Publishing Group 1 publication, 0.62%
IOP Publishing	IOP Publishing, 1, 0.62% IOP Publishing 1 publication, 0.62%
Cambridge University Press	Cambridge University Press, 1, 0.62% Cambridge University Press 1 publication, 0.62%
Taylor & Francis	Taylor & Francis, 1, 0.62% Taylor & Francis 1 publication, 0.62%
American Society of Health-System Pharmacists	American Society of Health-System Pharmacists, 1, 0.62% American Society of Health-System Pharmacists 1 publication, 0.62%
Royal College of Physicians	Royal College of Physicians, 1, 0.62% Royal College of Physicians 1 publication, 0.62%
American Society of Clinical Oncology (ASCO)	American Society of Clinical Oncology (ASCO), 1, 0.62% American Society of Clinical Oncology (ASCO) 1 publication, 0.62%
Publishing House ABV Press	Publishing House ABV Press, 1, 0.62% Publishing House ABV Press 1 publication, 0.62%
American Association for the Advancement of Science (AAAS)	American Association for the Advancement of Science (AAAS), 1, 0.62% American Association for the Advancement of Science (AAAS) 1 publication, 0.62%
EMBO press	EMBO press, 1, 0.62% EMBO press 1 publication, 0.62%
Moffitt Cancer Center	Moffitt Cancer Center, 1, 0.62% Moffitt Cancer Center 1 publication, 0.62%
AME Publishing Company	AME Publishing Company, 1, 0.62% AME Publishing Company 1 publication, 0.62%
	5 10 15 20 25 30

We do not take into account publications that without a DOI.
Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
Statistics recalculated weekly.

{"yearsCitations":{"type":"bar","data":{"show":true,"labels":[2019,2020,2021,2022,2023,2024],"ids":[0,0,0,0,0,0],"codes":[0,0,0,0,0,0],"imageUrls":["","","","","",""],"datasets":[{"label":"Citations number","data":[3,33,36,43,33,14],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":["1.85","20.37","22.22","26.54","20.37","8.64"],"barThickness":null}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"journals":{"type":"bar","data":{"show":true,"labels":["Molecules","Cancers","Frontiers in Pharmacology","Frontiers in Oncology","Biomedicines","International Journal of Molecular Sciences","Cells","PLoS Computational Biology","Future Medicinal Chemistry","Pharmaceutics","Bioorganic and Medicinal Chemistry Letters","ChemistrySelect","RSC Advances","Nutrition and Health","Current Pharmaceutical Design","Future Oncology","Oncotarget","DNA and Cell Biology","International Journal of Molecular Medicine","Journal of Neuro-Ophthalmology","Medicine (United States)","World Journal of Clinical Cases","Journal of Telemedicine and Telecare","Human and Experimental Toxicology","Vaccines","Frontiers in Endocrinology","Frontiers in Cell and Developmental Biology","Journal of Experimental and Clinical Cancer Research","Nature"],"ids":[1770,22471,9788,10990,24421,14627,25293,23198,22201,4502,8828,8021,3100,8294,12406,23962,8484,755,16008,24042,19945,2773,12509,16577,24868,19896,12128,5741,14611],"codes":[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/PRGhlgB4OKRltSNtT39eA6wlnOTGRap1QQ6FQHih_medium.webp","\/storage\/images\/resized\/AN2jnDN59NmKaS4CWLHAGstADL2DbnatQScsFA6C_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/leiAYcRDGTSl5B1eCnwpSGqmDEUEfDPPoYisFGhT_medium.webp","\/storage\/images\/resized\/ruydfaB80LDjlkYqsfOeUAZohOIODyq7bQzis5O7_medium.webp","\/storage\/images\/resized\/doUaFUZdxUEQjLi1TwZjGHi8HXYNWWSk04dSC6Xh_medium.webp","\/storage\/images\/resized\/AN2jnDN59NmKaS4CWLHAGstADL2DbnatQScsFA6C_medium.webp","\/storage\/images\/resized\/HY0CXgRt044tzIAB16PDvDzdHeKHGtSvlMH0yWf6_medium.webp","\/storage\/images\/resized\/Zy5YST233rzRbZP24I24MzZm64hz20ZV9qQopmMn_medium.webp","\/storage\/images\/resized\/8zKfOwdd5XirYzTQfqwp7U8IEQc8ckIOjyYQSBkk_medium.webp","\/storage\/images\/resized\/6QE8LXWrLpkoy5A2te6hw7who46GeCoTYIstuoAz_medium.webp","\/storage\/images\/resized\/6QE8LXWrLpkoy5A2te6hw7who46GeCoTYIstuoAz_medium.webp","\/storage\/images\/resized\/bKOjgSt9mSGUD9fzKZyqcKSIgDCDSMd1ZWjJOZzx_medium.webp","\/storage\/images\/resized\/ruydfaB80LDjlkYqsfOeUAZohOIODyq7bQzis5O7_medium.webp","\/storage\/images\/resized\/ruydfaB80LDjlkYqsfOeUAZohOIODyq7bQzis5O7_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp"],"datasets":[{"label":"","data":[6,5,4,4,4,3,3,2,2,2,2,2,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[3.7,3.09,2.47,2.47,2.47,1.85,1.85,1.23,1.23,1.23,1.23,1.23,1.23,0.62,0.62,0.62,0.62,0.62,0.62,0.62,0.62,0.62,0.62,0.62,0.62,0.62,0.62,0.62,0.62],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Journals","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"publishers":{"type":"bar","data":{"show":true,"labels":["Elsevier","Springer Nature","Multidisciplinary Digital Publishing Institute (MDPI)","Wiley","Frontiers Media S.A.","Future Medicine","SAGE","Bentham Science","Public Library of Science (PLoS)","Wolters Kluwer Health","American Chemical Society (ACS)","Spandidos Publications","Royal Society of Chemistry (RSC)","Open Exploration Publishing","Hindawi Limited","Impact Journals","Mary Ann Liebert","Baishideng Publishing Group","IOP Publishing","Cambridge University Press","Taylor & Francis","American Society of Health-System Pharmacists","Royal College of Physicians","American Society of Clinical Oncology (ASCO)","Publishing House ABV Press","American Association for the Advancement of Science (AAAS)","EMBO press","Moffitt Cancer Center","AME Publishing Company"],"ids":[17,8,202,11,208,6949,31,39,344,32,40,1097,123,7507,6921,342,230,7719,2075,1,18,5437,2766,73,7001,189,9415,5824,1566],"codes":[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/AN2jnDN59NmKaS4CWLHAGstADL2DbnatQScsFA6C_medium.webp","\/storage\/images\/resized\/ruydfaB80LDjlkYqsfOeUAZohOIODyq7bQzis5O7_medium.webp","\/storage\/images\/resized\/doUaFUZdxUEQjLi1TwZjGHi8HXYNWWSk04dSC6Xh_medium.webp","\/storage\/images\/resized\/PRGhlgB4OKRltSNtT39eA6wlnOTGRap1QQ6FQHih_medium.webp","\/storage\/images\/resized\/6QE8LXWrLpkoy5A2te6hw7who46GeCoTYIstuoAz_medium.webp","\/storage\/images\/resized\/iLiQsFqFaSEx6chlGQ5fbAwF6VYU3WWa08hkss0g_medium.webp","\/storage\/images\/resized\/8zKfOwdd5XirYzTQfqwp7U8IEQc8ckIOjyYQSBkk_medium.webp","\/storage\/images\/resized\/leiAYcRDGTSl5B1eCnwpSGqmDEUEfDPPoYisFGhT_medium.webp","","\/storage\/images\/resized\/hqfzhQAjTGlNSRs6yzFNITgjSMm9Jr2QuotJHIvE_medium.webp","\/storage\/images\/resized\/HY0CXgRt044tzIAB16PDvDzdHeKHGtSvlMH0yWf6_medium.webp","\/storage\/images\/resized\/Zy5YST233rzRbZP24I24MzZm64hz20ZV9qQopmMn_medium.webp","\/storage\/images\/resized\/bKOjgSt9mSGUD9fzKZyqcKSIgDCDSMd1ZWjJOZzx_medium.webp","\/storage\/images\/resized\/LsKy6OnmmmRGcAU6CZgWQvNiP1polbaSLNrN7zqj_medium.webp","\/storage\/images\/resized\/cF81zWlLdkmYekymGuDcSdvgBGNKaIDoMoeJtHS1_medium.webp","\/storage\/images\/resized\/5YZtvLvkPZuc2JHOaZsjCvGSHFCuC3drUwN3YAc5_medium.webp","\/storage\/images\/resized\/1m3LXY50cNi8fI7nCBdvoi4rhQMp4gd6vmoowUF7_medium.webp","","\/storage\/images\/resized\/0WrbuCPHoMon4eqSaqLoeO1owjv6jeDiHASSYzbS_medium.webp","\/storage\/images\/resized\/h7VqwIS9SIdw1p0X0HgUDKwed9MCAt9vlf7wMp3w_medium.webp","\/storage\/images\/resized\/s10mcsCV4OAUg9O2KrqOquQC0PhyLMI8hUUkuflM_medium.webp","\/storage\/images\/resized\/1UiI5HycPsvulDeXOySNp0OuaMMmIKfPnsdKPyH0_medium.webp","\/storage\/images\/resized\/cMUbANkfuFINkjHIzWpugeHVvj3BhL2T5MmIm9X0_medium.webp","\/storage\/images\/resized\/PYBAYQjpFdxPQPRGY3kU5Xzbu0W7K7umVNk0TY9i_medium.webp"],"datasets":[{"label":"","data":[27,25,24,13,10,4,3,3,3,3,3,2,2,2,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[16.67,15.43,14.81,8.02,6.17,2.47,1.85,1.85,1.85,1.85,1.85,1.23,1.23,1.23,1.23,0.62,0.62,0.62,0.62,0.62,0.62,0.62,0.62,0.62,0.62,0.62,0.62,0.62,0.62],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Publishers","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}}}

Publication PDF

Metrics

Cite this

GOST |

Cite this

GOST Copy

Seebacher N. A. et al. Clinical development of targeted and immune based anti-cancer therapies // Journal of Experimental and Clinical Cancer Research. 2019. Vol. 38. No. 1. 156

GOST all authors (up to 50) Copy

Seebacher N. A., Stacy A. E., Porter G. M., Merlot A. M. Clinical development of targeted and immune based anti-cancer therapies // Journal of Experimental and Clinical Cancer Research. 2019. Vol. 38. No. 1. 156

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1186/s13046-019-1094-2

UR - https://doi.org/10.1186%2Fs13046-019-1094-2

TI - Clinical development of targeted and immune based anti-cancer therapies

T2 - Journal of Experimental and Clinical Cancer Research

AU - Seebacher, N A

AU - Stacy, A E

AU - Porter, G M

AU - Merlot, Angelica M

PY - 2019

DA - 2019/04/11 00:00:00

PB - Springer Nature

IS - 1

VL - 38

PMID - 30975211

SN - 0392-9078

SN - 1756-9966

ER -

BibTex

Cite this

BibTex Copy

@article{2019_Seebacher,

author = {N A Seebacher and A E Stacy and G M Porter and Angelica M Merlot},

title = {Clinical development of targeted and immune based anti-cancer therapies},

journal = {Journal of Experimental and Clinical Cancer Research},

year = {2019},

volume = {38},

publisher = {Springer Nature},

month = {apr},

url = {https://doi.org/10.1186%2Fs13046-019-1094-2},

number = {1},

doi = {10.1186/s13046-019-1094-2}

}

Found error?

Publisher

Springer Nature

Journal

Journal of Experimental and Clinical Cancer Research

Quartile SCImago

Quartile WOS

Impact factor

11.3

ISSN

03929078 (Print)
17569966 (Electronic)